Currently out of the existing stock ratings of Matthew Biegler, 110 are a BUY (91.67%), 10 are a HOLD (8.33%).

Matthew Biegler

Work Performance Price Targets & Ratings Chart

Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 31.07% that have a potential upside of 37.21% achieved within 139 days.

Matthew Biegler’s has documented 218 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RLAY, Relay Therapeutics at 26-Jan-2026.

Wall Street Analyst Matthew Biegler

Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for OLMA (OLEMA PHARMACEUTICALS) at 9/3/2025. The price target of $22 was fulfilled within 78 days with a profit of $15.71 (249.76%) receiving and performance score of 32.02.

Average potential price target upside

of $102.15 (58.44%) on APTO (APTOSE BIOSCIENCES).
of $29.3 (61.94%) on CELU (CELULARITY).
of $21.06 (24.88%) on TPTX (TURNING POINT THERAPEUTICS).

FATE Fate Therapeutics MRKR Marker Therapeutics TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BPMC Blueprint Medicines Corp FIXX Homology Medicines FULC Fulcrum Therapeutics NKTX Nkarta VOR Vor Biopharma CELU Celularity MDNA Medicenna Therapeutics Corp TYRA Tyra Biosciences IDYA Ideaya Biosciences RLAY Relay Therapeutics PRTG Portage Biotech APTO Aptose Biosciences OLMA Olema Pharmaceuticals DAWN Day One Biopharmaceuticals ALLO Allogene Therapeutics ARVN Arvinas ORIC Oric Pharmaceuticals RNAC Cartesian Therapeutics NRIX Nurix Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Robert Burns (HC WAINWRIGHT)